Bristol-myers Squibb Compnay

Amgen Inc.

Bristol-myers Squibb

Leon M Smith, Ii

Donald J P Pinto

James R Corte

Michael J Orwat

William R Ewing

Wu Yang

Yufeng Wang

Paul Joseph Gilligan

Tianan Fang

Andrew K Dilger

Kumar Balashanmuga Pabbisetty

Shefali Srivastava

Indawati De Lucca

Ruth Richmond Wexler

Yeheng Zhu

Mimi Lifen Quan

Celia Dominguez

Ning Xi

Andrew Stewart Tasker

Joseph L Kim

Vinod Francis Patel

Daniel Elbaum

Joanne M Smallheer

Shimin Xu

Zilun Hu

Chester Chenguang Yuan

Qi Huang

Charles G Clark

Tae-Seong Kim

Guoqing Paul Chen

Michael D Croghan

Cullen L Cavallaro

Julie Germain

Jean E Bemis

Shon Booker

Guolin Cai

Yoon T Jeon

Jeffrey A Adams

Michael K Handley

Lucian V Di Pietro

Xiaohu Ouyang

Peter W Glunz

Markian Myroslaw Stec

Patrick Y S Lam

Stephanie Geuns-Meyer

Manoranjan Panda

Vladimir Ladziata

Scott A Shaw

Alexander S Kiselyov

Nobuko Nishimura

Lucian V DiPietro

Aiwen Li

Gregory J Habgood

Benny C Askew, Jr

Indawati DeLucca

Donald Jp Pinto

Charles G Clarke

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Pyrimidinones as factor XIA inhibitors

The present invention provides compounds of Formula (1): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

The present invention provides compounds of Formula (I): (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Substituted glycine derived FXIA inhibitors

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

Spiroheptane salicylamides and related compounds as inhibitors of ROCK

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same. 

Spiroheptane salicylamides and related compounds as inhibitors of rock

Pyrimidinones as factor XIa inhibitors

The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Macrocyclic factor XIa inhibitors bearing heterocyclic groups

The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.

Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same. 

Diamide macrocycles as factor XIa inhibitors

Substituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridines as factor XIa inhibitors

The present invention provides compounds of Formula (V):  or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Dihydropyridone P1 as factor XIa inhibitors

The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Macrocycles as factor XIa inhibitors

Macrocycles with aromatic P2' groups as factor xia inhibitors

Growing community of inventors

Somerset, NJ, United States of America

Leon M Smith, Ii